MYCL and Merkel cell skin cancer: Multiple lines of evidence suggestion that both L-myc and AKT could potentially be druggable targets in the treatment of MCC [14,50,51], and assessing CNV signature type may help predict which MCC tumors are more likely to respond to these treatments.